Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has been diagnosed with type 2 diabetes mellitus~* Has hemoglobin-specific A1c fraction (HbA1c) of 7.1% to 11.0%, inclusive, at screening~* Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive, at screening~* Has been treated with diet and exercise alone or in combination with a stable regimen of metformin (MET), a sulfonylurea (SU), a thiazolidinedione (TZD), a combination of metformin and an SU, a combination of metformin and a TZD, or a combination of an SU and a TZD for a minimum of 2 months prior to screening~* Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to screening:~  * Hormone replacement therapy (female subjects)~ * Oral contraceptives (female subjects)~ * Antihypertensive agents~ * Lipid-lowering agents~ * Thyroid replacement therapy~ * Antidepressant agents~ * Drugs known to affect body weight, including prescription medications (e.g. orlistat \[XENICAL®\], sibutramine \[MERIDIA®\], topiramate \[TOPAMAX®\]) and over the counter antiobesity agents~Exclusion Criteria:~* Has ever been exposed to exenatide (exenatide once weekly \[exenatide LAR\], exenatide BID, BYETTA, or any other formulation) or any glucagon-like peptide-1 (GLP-1) analog~* Has received any investigational drug within one month (or five half-lives of the investigational drug, whichever is greater) of screening~* Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following treatment excluded medications:~  * Any dipeptidyl peptidase 4 (DPP-4) inhibitor within 3 months prior to screening~ * Alpha glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®) within 30 days of screening~ * Insulin within 2 weeks of screening or for more than 1 week within 3 months of screening~ * Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known to have a high rate of systemic absorption

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).